Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.74 |
| ▸ | ITK | Q08881 | 9/20 | 0.73 |
| ▸ | EGFR | P00533 | 11/20 | 0.61 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498142 | 0.95 | ITK (0.71) | BTKITKEGFRCNR2 | |
| SCHEMBL21110447 | 0.90 | BTK (0.91) | BTKITKEGFRJAK3CNR2 | |
| SCHEMBL13185112 | 0.88 | CNR2 (0.61) | BTKITKEGFRCNR2 | |
| SCHEMBL14771996 | 0.87 | BTK (0.72) | BTKITKEGFRJAK3CNR2 | |
| SCHEMBL12519590 | 0.87 | CNR2 (0.60) | BTKITKEGFRCNR2 | |
| SCHEMBL12519517 | 0.87 | ITK (0.84) | BTKITKEGFR | |
| SCHEMBL12519584 | 0.86 | CNR2 (0.58) | BTKITKEGFRCNR2 | |
| SCHEMBL21109653 | 0.85 | ITK (0.84) | BTKITKEGFR | |
| SCHEMBL12519472 | 0.85 | BTK (1.00) | BTKITKEGFRJAK3 | |
| SCHEMBL29722282 | 0.85 | ITK (1.00) | BTKITKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-9409921-B2 | 2,4-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9296737-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9212181-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | BTK 594/4885ITK 2697/4885EGFR 1981/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | BTK 594/4885ITK 2697/4885EGFR 1981/4885 |
| US-20130072469-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | BTK 594/4885ITK 2697/4885EGFR 1981/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | BTK 261/4885ITK 317/4885EGFR 460/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | BTK 149/4885ITK 352/4885EGFR 176/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | BTK 594/4885ITK 2697/4885EGFR 1981/4885 |
| US-20130165462-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | BTK 594/4885ITK 2697/4885EGFR 1981/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | BTK 594/4885ITK 2697/4885EGFR 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.